Get the latest news, insights, and market updates on LIVN (LivaNova PLC). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LONDON, December 03, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (AES) Annual Meeting, taking place Dec. 5-9 in Atlanta. These presentations highlight real-world evidence from the CORE-VNS study, the largest prospective, multinational observational study of VNS Therapy™ for Drug-Resistant Epilepsy (DRE), and new health economics analyses. Dec 3, 2025 - $LIVN
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LONDON, December 02, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective December 1. Blaise reports to Vladimir Makatsaria, Chief Executive Officer and is a member of the Executive Leadership Team. Dec 2, 2025 - $LIVN
A Look at LivaNova's (LIVN) Valuation Following Its Recent 20% Share Price Surge
LivaNova (LIVN) has caught investors’ attention lately as its share price climbed nearly 20% in the past month. This uptick comes amid a steady stream of updates from the medical technology company. See our latest analysis for LivaNova. The recent 19.6% one-month share price return for LivaNova stands out, especially as the stock is now up over 36% for the year to date. Positive investor sentiment has been building after a strong stretch of updates. While the 1-year total shareholder return... Nov 29, 2025 - $LIVN
LivaNova to Present at Piper Sandler Healthcare Conference in December
LONDON, November 25, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York City. The presentation will take place on Tues., Dec. 2, at 1:30 p.m. Eastern Standard Time. Nov 25, 2025 - $LIVN
LivaNova’s VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
LONDON, November 24, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assigned VNS Therapy™, a LivaNova neuromodulation treatment for patients 4 years of age and older with Drug-Resistant Epilepsy (DRE) and focal seizures, to New Technology Ambulatory Payment Classification (APC) 1580 for new patient implants (NPIs) under the 2026 Medicare Hospital Outpatient Prospective Payment System. CM Nov 24, 2025 - $LIVN
What LivaNova (LIVN)'s Q3 Revenue Growth and China Launch Mean For Shareholders
On November 5, 2025, LivaNova PLC reported that third-quarter sales rose to US$357.75 million from US$318.12 million a year earlier, with its cardiopulmonary and epilepsy segments driving growth, while net income fell to US$26.78 million from US$32.95 million. The company launched the Essenz heart-lung machine in China and raised its full-year revenue guidance, signaling confidence in ongoing business expansion despite recent profit pressures. We'll explore how the strong revenue growth and... Nov 9, 2025 - $LIVN
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
LONDON, November 05, 2025--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-year 2025 guidance. Nov 5, 2025 - $LIVN
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple